infohep news

• Hepatocellular carcinoma (HCC)

  Sustained response to HCV antivirals boosts liver cancer survival

  Liz Highleyman / 19 November 2019

  People with liver cancer who achieved a sustained virological response (SVR) to direct-acting antiviral (DAA) therapy for hepatitis C saw a reduction in both liver-related and all-cause mortality over five years, according to ...

• Hepatocellular carcinoma (HCC)

  Hepatitis B antiviral drugs reduce liver cancer risk

  Liz Highleyman / 19 November 2019

  Treating hepatitis B virus (HBV) with nucleoside/nucleotide antiviral drugs was associated with a lower risk of developing hepatocellular carcinoma (HCC), the most common type of liver cancer, according to studies presented last week ...

• Sexual transmission

  Hepatitis C incidence is low among Canadian men on PrEP

  Liz Highleyman / 18 November 2019

  New cases of hepatitis C virus (HCV) infection among Canadian gay and bisexual men taking pre-exposure prophylaxis (PrEP) were uncommon compared with rates previously reported in Europe, according to research ...

• Transplants from donors with HCV

  Pre- and post-transplant antiviral treatment prevents hepatitis C transmission in all organ recipients, Canadian study finds

  Keith Alcorn / 14 November 2019

  Adding a cholesterol-lowering drug to direct-acting antivirals prevented hepatitis C infection in all recipients of organ transplants from donors with hepatitis C, Jordan Feld, Research Director, Toronto Centre for Liver Disease, reported at ...

• Hepatitis C elimination

  Coalition of liver associations calls for simplifying hepatitis C care

  Liz Highleyman / 13 November 2019

  Leaders of liver disease associations from Europe, the United States, Latin America and Asia issued a global call to action at the AASLD Liver Meeting this week in Boston, aiming to advance ...